Biogen Appoints David M. Buckley Executive Vice President, Technical Operations

Apr 19, 2001, 01:00 ET from Biogen, Inc.

    CAMBRIDGE, Mass, April 19 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN)
 today announced that David M. Buckley has been appointed Executive Vice
 President, Technical Operations.  Mr. Buckley reports to James C. Mullen,
 President and Chief Executive Officer.
     ( Photo:  http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
     Mr. Buckley joins Biogen from General Electric Company (GE), where he was
 most recently President and Chief Executive Officer of TIMM Communications,
 Inc., a Portfolio Company of GE Capital. Since 1998, he served in senior and
 general management positions at GE, including Senior Vice President, e-
 Business Leader and Global Process Leader of GE's premier quality program,
 Six-Sigma.  Prior to joining GE, Mr. Buckley was a senior manager and
 principal consultant with PricewaterhouseCoopers.  He also has held positions
 as a general plant and manufacturing manager. Mr. Buckley graduated from the
 United States Naval Academy and earned an MBA from the Wharton School.
     Mr. Mullen said, "We are very fortunate to have David Buckley join our
 senior management team in this newly created position.  The breadth of his
 experience in technical operations, manufacturing and quality are critical
 strengths that will augment Biogen's team and help to drive us to the next
 level of excellence in our technical and manufacturing operations.   Biogen is
 at the forefront in manufacturing capacity and capability and David's
 leadership will help ensure that manufacturing remains one of this company's
 vital strategic assets."
 
     Biogen, Inc., winner of the U.S. National Medal of Technology, is a
 biopharmaceutical company principally engaged in discovering and developing
 drugs for human healthcare through genetic engineering.  Headquartered in
 Cambridge, MA, the Company's revenues are generated from international sales
 of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
 sclerosis, and from the worldwide sales by licensees of a number of products,
 including alpha interferon and hepatitis B vaccines and diagnostic products.
 Biogen's research and development activities are focused on novel products to
 treat inflammatory and autoimmune diseases, neurological diseases, cancer,
 fibrosis and congestive heart failure.  The Company maintains active clinical
 research programs in protein therapeutics, small molecules, genomics and gene
 therapy.  For copies of press releases and additional information about the
 Company, please consult Biogen's Homepage on the World Wide Web at
 http://www.biogen.com
 
 

SOURCE Biogen, Inc.
    CAMBRIDGE, Mass, April 19 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN)
 today announced that David M. Buckley has been appointed Executive Vice
 President, Technical Operations.  Mr. Buckley reports to James C. Mullen,
 President and Chief Executive Officer.
     ( Photo:  http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
     Mr. Buckley joins Biogen from General Electric Company (GE), where he was
 most recently President and Chief Executive Officer of TIMM Communications,
 Inc., a Portfolio Company of GE Capital. Since 1998, he served in senior and
 general management positions at GE, including Senior Vice President, e-
 Business Leader and Global Process Leader of GE's premier quality program,
 Six-Sigma.  Prior to joining GE, Mr. Buckley was a senior manager and
 principal consultant with PricewaterhouseCoopers.  He also has held positions
 as a general plant and manufacturing manager. Mr. Buckley graduated from the
 United States Naval Academy and earned an MBA from the Wharton School.
     Mr. Mullen said, "We are very fortunate to have David Buckley join our
 senior management team in this newly created position.  The breadth of his
 experience in technical operations, manufacturing and quality are critical
 strengths that will augment Biogen's team and help to drive us to the next
 level of excellence in our technical and manufacturing operations.   Biogen is
 at the forefront in manufacturing capacity and capability and David's
 leadership will help ensure that manufacturing remains one of this company's
 vital strategic assets."
 
     Biogen, Inc., winner of the U.S. National Medal of Technology, is a
 biopharmaceutical company principally engaged in discovering and developing
 drugs for human healthcare through genetic engineering.  Headquartered in
 Cambridge, MA, the Company's revenues are generated from international sales
 of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
 sclerosis, and from the worldwide sales by licensees of a number of products,
 including alpha interferon and hepatitis B vaccines and diagnostic products.
 Biogen's research and development activities are focused on novel products to
 treat inflammatory and autoimmune diseases, neurological diseases, cancer,
 fibrosis and congestive heart failure.  The Company maintains active clinical
 research programs in protein therapeutics, small molecules, genomics and gene
 therapy.  For copies of press releases and additional information about the
 Company, please consult Biogen's Homepage on the World Wide Web at
 http://www.biogen.com
 
 SOURCE  Biogen, Inc.